Phase 4 N=15 SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy
Primary: Number of Participants Who Experienced a Serious Adverse Event (SAE) — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 Measuring and Improving the Safety of Test Result Follow-Up
Lung Cancer · Breast Cancer · Colon Cancer
Primary: Trigger Outcome — 67.0; 65.9; 78.6; 78.1 percentage of abnormal tests w/ followup
N/A N=36 SmarToyGym: Smart Detection of Atypical Toy-oriented Actions in At-risk Infants
Cerebral Palsy · Developmental Delay · Stroke
Primary: Center of Pressure, Path Length Per Second - No Toy (Birth Status) — 0.0282; 0.0428 centimeters per second (cm/sec) — p=0.0054
N/A N=270 Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression
Venous Vascular Closure
Primary: Primary Safety Endpoint: Major Complications of the Target Limb Access Site Within 30 Days — 0; 1 limbs
N/A N=40 Clinical Validation Study for Noninvasive Cardiopulmonary Management Device
Cardiopulmonary Disease
Primary: Correlation Coefficient for Accuracy of Test Device vs Reference Device — 0.99; 0.95 Correlation Coefficient
Phase 3 N=131 A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
Chronic Cluster Headache
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 106 Participants
N/A N=113 Clinical Performance Assessment of Two Silicone Hydrogel Daily Disposable Contact Lenses
Refractive Errors · Myopia
Primary: Least Squares Mean Distance Visual Acuity (VA) With Study Lenses at Day 4 — -0.13; -0.13 logMAR
N/A N=99,659 A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth
Post-Partum Haemorrhage
Primary: The Primary Outcome is a Composite of the Following Three Clinical Outcomes: 1) Severe PPH Defined as Blood Loss ≥1000 ml or; 2) Postpartum Laparotomy for Bleeding or…
Phase 1 N=9 Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance
Sepsis
Primary: Imipenem Clearance — 17.31 L/h
N/A N=56 Feasibility and Clinical Utility of the Dexcom G6 Continuous Glucose Monitoring Device for Type 2 Diabetes
Type 2 Diabetes
Primary: Change in Average Glucose Levels as Measured by Continuous Glucose Monitor — 184; 148.6; 144.8; 147.2 mg/dl
Phase 1 N=25 A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects
Healthy Volunteer Study
Primary: Plasma Oxytocin Concentration 2 Minutes After Infusion Initiated — 105 picograms/ml of oxytocin
Early Phase 1 N=12 Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus · Obesity
Primary: Glucose Infusion Rate — 532; 557 microunits per milliliter
N/A N=246 DWI Offenders and Their Families App for Smartphones
Coping Skills · Family Relations
Primary: Measure of Primary Outcome Variable: IID Lockout Events. — 10.13; 2.78 Ignition Interlock Lockout Events — p=.04
N/A N=74 Reducing Potentially Inappropriate Medication Prescribing for Older Patients in the ED
Aging
Primary: Percentage of PIMs Prescribed — 1,672; 2,979 Prescriptions
Phase 1 N=34 Mavoglurant in Alcohol Drinking
Alcohol Drinking
Primary: Abnormal Labs and Adverse Events — 9; 8; 0; 0 Participants